INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer

Go Back to All Clinical Trials

INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer

Brief description of study

The purpose of the trial is to determine whether Darolutamide plus radiation therapy (RT) is non-inferior to gonadotropin releasing hormone (GnRH) agonist and bicalutamide plus RT for intermediate risk prostate cancer. The goal of this trial is to determine whether men who receive Darolutamide with RT are better able to preserve erectile function without sacrificing the potential for long-term disease control.

Clinical Study Identifier: s20-01236

ClinicalTrials.gov Identifier: NCT04025372

Principal Investigator: Aaron Edward Katz.

Other Investigators: Hank Ng, Peter B. Schiff, Andrew J Evans, Minas Platon Economides, Anthony Corcoran, Thomas B. Daniels, Michael J. Zelefsky, Jonathan W Lischalk, Victor Ricardo Adorno Febles, Scot Niglio, Todd J Carpenter, Jeffrey Todd Schiff, Jonathan Haas, James R Lewis, David Jaihun Byun, David R. Wise.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies